Press release from Companies
Publicerat: 2024-11-22 15:45:34
New cut-off date allows additional time to finalize shareholder holdings and ensures accuracy in share distribution.
CS MEDICA A/S (CSMED) announces that the share distribution of CANNORDIC shares has been extended. The distribution, originally planned for shareholders registered as of today, November 22, 2024, will now be based on a new cut-off date. This adjustment is to ensure accuracy in the distribution process but also provides shareholders additional time to maximize their participation in the share distribution.
Key Details:
This update reflects CS MEDICA’s dedication to ensuring a fair, transparent, and precise distribution process that benefits all shareholders. The company remains focused on completing the distribution efficiently and will share further updates as the process progresses.
Thank you for your understanding and continued support. For the latest updates, please visit cs-medica.com.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.